

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived mouse PD-L1/B7-H1 protein			
	Mouse B7-H1 (Phe19-Thr238) Accession # Q9EP73.1 N-terminus	IEGRMD	Human IgG ₁ (Pro100-Lys330)	Avi-tag C-terminus
N-terminal Sequence	Phe19			
Analysis				
Structure / Form	Biotinylated via Avi-tag			
Predicted Molecular Mass	53 kDa			

SPECIFICATIONS

SDS-PAGE	67-85 kDa, under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA. When Recombinant Mouse PD-1 Fc Chimera Protein (Catalog # 1021-PD) is immobilized at 2.50 µg/mL (100 µL/well), Biotinylated Recombinant Mouse PD-L1/B7-H1 Fc Chimera Avi-tag (Catalog # AV11019) binds with an ED ₅₀ of 0.0600-0.600 µg/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 250 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA

<p>Binding Activity</p> <p>Biotinylated Recombinant Mouse PD-L1/B7-H1 Fc Chimera Avi-tag Protein Binding Activity. Measured by its binding ability in a functional ELISA. When Recombinant Mouse PD-1 Fc Chimera Protein (Catalog # 1021-PD) is immobilized at 2.5 µg/mL (100 µL/well), Biotinylated Recombinant Mouse PD-L1/B7-H1 Fc Chimera Avi-tag Protein (Catalog # AV11019) binds with an ED₅₀ of 0.0600-0.600 µg/mL.</p>	<p>SDS-PAGE</p> <p>Biotinylated Recombinant Mouse PD-L1/B7-H1 Fc Chimera Avi-tag Protein SDS-PAGE. 2 µg/lane of Biotinylated Recombinant Mouse PD-L1/B7-H1 Fc Chimera Avi-tag Protein (Catalog # AV11019) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 67-85 kDa and 130-170 kDa, respectively.</p>
--	--

BACKGROUND

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature mouse B7-H1 consists of a 221 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain (2). Within the ECD, mouse B7-H1 shares 73% and 86% aa sequence identity with human and rat B7-H1, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (2-5), keratinocytes (6, 7), endothelial and intestinal epithelial cells (6, 8), as well as a variety of carcinomas and melanoma (9, 10). B7-H1 binds to T cell B7-1/CD80 and PD-1 (5, 6, 10-13). It suppresses T cell activation and proliferation (3, 6, 12, 14) and induces the apoptosis of activated T cells (9). It plays a role in the development of immune tolerance by promoting T cell anergy (5, 12) and enhancing regulatory T cell development (14). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (3, 8) and inhibits the development of Th17 cells (14). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (4, 7, 10, 13). Our Avi-tag Biotinylated mouse B7-H1 Fc Chimera features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References:

1. Ceeraz, S. *et al.* (2013) Trends Immunol. **34**:556.
2. Tamura, H. *et al.* (2001) Blood **97**:1809.
3. Chen, L. *et al.* (2007) J. Immunol. **178**:6634.
4. Kuang, D.-M. *et al.* (2014) J. Clin. Invest. **124**:4657.
5. Tsushima, F. *et al.* (2007) Blood **110**:180.
6. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. **169**:3581.
7. Cao, Y. *et al.* (2010) Cancer Res. **71**:1235.
8. Scanduzzi, L. *et al.* (2014) Cell Rep. **6**:625.
9. Dong, H. *et al.* (2002) Nat. Med. **8**:793.
10. Azuma, T. *et al.* (2008) Blood **111**:3635.
11. Butte, M.J. *et al.* (2008) Mol. Immunol. **45**:3567.
12. Park, J.-J. *et al.* (2010) Blood **116**:1291.
13. Ritprajak, P. *et al.* (2010) J. Immunol. **184**:4918.
14. Herold, M. *et al.* (2015) J. Immunol. **195**:3584.